Member Info for TRENCH123

Bassman, it is a site for 'share chat' and not 'investment advice' and you are intelligent enough surely to understand this. Give it a rest

Satan, don't get so excited and post on the relevant board please.

PYC worked on both ANK-101 (for Ankyra) and NM81 (for Numab), hence the links

Https://www.numab.com/wp-content/uploads/251113_PR_Kaken-and-Numab-Therapeutics-Announce-License-Agreement-NM81.pdf

https://ankyratx.com/wp-content/uploads/2025/11/2025.11.17-Lantern-FPI-Press-Release-Final-Nov-2025__.pdf

DeBull, I agree totally. Some very immature people posting today bearing grudges. Sadly, they have not got the temperament to invest on AIM

Genuinely very tight spread at moment on buys/sells of c £500

Contracts are running concurrently and not in isolation. News is expected, whether it falls before or after next week's AGM remains to be seen

The spread is around 0.40-0.42 for normal volume trades. 0.38 was given for a £5.00 sale, so atypical

The range is a completely normal trading range for AIM

But as mentioned yesterday it is a false spread for typical transactions The true spread is much smaller, around 0.40-0.42, so absolutely normal for AIM

PYC are exploring the development of new dosing tools beyond Docetaxel and G-CSF with DosemeRx. Pete Sargent mentioned at the recent IMC presentation that they would be 'sure to provide further feedback and announcements as we progress the expanded partnership'

News due soon, hopefully

It is just lazy MM's. The true spread is currently around 0.39-0.40

As everybody here knows, this moves fast on news (and without news, as recently)

PYC must have a good idea as to how a dosing tool commercial agreement would look. Jim did mention in March that PYC should be able to provide some metrics as to the potential size of the market for the tool in the US at some stage

North, it is very important that you take information from as many sources as possible and own your decision

Essential that you watch the Investor Meet Company presentation from around one month ago.

'The Department for Science, Innovation and Technology has today (Thursday 30 October) confirmed long-term R&D funding for the UK’s research agencies and bodies, with bumper investment for the bodies that are making science and tech breakthroughs that improve lives and grow our economy'

https://www.gov.uk/government/news/55-billion-rd-funding-boost-to-unlock-uk-breakthroughs-from-health-to-clean-energy

Trout, if you are unhappy then sell up here (as you said you would a while back) and put the extra into FAB. Speak to PS directly if you are genuinely interested and have unanswered questions

PYC is a decent well-respected company with potential on numerous fronts. The share price has traded in the 0.40-0.50 range for months. I believe it will break out permanently once material news on its various collaborations is released

King H, your thoughts about Elevara make good sense. PS did comment on the fantastic leads which had resulted from their association with Weatherden

Significantly undervalued IMHO and news not far away hopefully. I am perfectly happy to be invested here

Trout, I have every respect for the integrity of the CEO of Beyond Blood. Surely you are not suggesting that he would post a dodgy link ?

Not too long ago the CEO of Beyond Blood highlighted an article on specialist grants available in the sector on his LinkedIn account (article link no longer visible). I think it could have been this one :-

uk-business-connect.org.uk/opportunities/innovate-uk-biomedical-catalyst-accelerator-hospital-to-community/